Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Obinutuzumab for treating lupus nephritis ID 6420Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC